Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

The 64-week trial is comparing Novartis’ drug with the current formulation of Eylea, while last year the FDA approved a 12 ... in the wet AMD market is off-label use of Roche’s VEGF inhibitor ...

Jefferies’ own review of the FDA Adverse Event Reporting System database ... blindness and eye inflammation on Beovu since launch compared with either Eylea or Lucentis, although these reports ...

In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...

Merck (MRK) stock in focus as the FDA approves its anticancer agent Welireg for two rare neuroendocrine tumors, expanding its ...

The FDA is the federal agency that oversees the "safety, nutritional adequacy, packaging, and labeling" of infant formula products, according to its website. When an infant formula is brought to ...

The Food and Drug Administration (FDA) announced Tuesday it will be moving to take ingestible prescription fluoride products for children off the market, citing concerns that the mineral alters ...

The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and ...

Stacey Leasca is an award-winning journalist with nearly two decades of newsroom experience. She is also the co-founder of Be a Travel Writer, an online course for the next generation of travel ...

RxDx assay as a companion diagnostic to identify c-Met protein expression in non-squamous NSCLC patients eligible for treatment with Emrelis.

Regeneron anticipates a decline in EYLEA sales due to biosimilar competition. DUPIXENT continues to expand globally, with significant growth expected by 2030. The company is investing $7 billion ...